Previous studies have shown that in a phase II clinical trial in patients with active RA, administration of CF101—a specific A3R agonist—resulted in amelioration of disease that, however, did not reach statistical significance [ 103 , 104 ].
← all excerpts
Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity.
1
—
—